ARDX
Ardelyx Inc.
$6.26
+$0.14(+2.37%)
45
Overall
40
Value
45
Tech
50
Quality
Market Cap
$1.50B
Volume
1.36M
52W Range
$3.49 - $8.40
Target Price
$16.44
Company Overview
| Mkt Cap | $1.50B | Price | $6.26 |
| Volume | 1.36M | Change | +2.37% |
| P/E Ratio | -24.4 | Open | $6.16 |
| Revenue | $407.3M | Prev Close | $6.11 |
| Net Income | $-61.6M | 52W Range | $3.49 - $8.40 |
| Div Yield | N/A | Target | $16.44 |
| Overall | 45 | Value | 40 |
| Quality | 50 | Technical | 45 |
No chart data available
About Ardelyx Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest News
Ardelyx Earnings Call Highlights Rapid Growth, Rising Costs
TipRanks Auto-Generated Newsdesk•7 days ago
Ardelyx Earnings Call: Ibsrela Surge Fuels Bold Targets
TipRanks Auto-Generated Newsdesk•25 days ago
Ardelyx Posts Strong Q1 2026 Revenue, Reaffirms Guidance
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARDX | $6.26 | +2.4% | 1.36M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |